Table 1.
Characteristics of HIV-infected patients at initiation of antiretroviral therapy in ten African countries, 2010–2012 (N = 3579)
| Benin | Burkina Faso | Cameroon | Cote d’Ivoire | Kenya | Senegal | South Africa | Togo | Uganda | Zambia | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of sites | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Cities | Cotonou | Bobo Dioulasso | Limbé | Abidjan | Eldoret | Dakar | Stellenbosch | Lomé | Kampala | Lusaka |
| Type of care | Tertiary | Tertiary | Tertiary | Primary / Tertiary | Tertiary | Tertiary | Tertiary | Tertiary | Tertiary | Primary |
| Number of patients included (proportion of total population followed) | 300 (30%) |
300 (21%) |
298 (~30%) |
900 (20%) |
299 (1%) |
297 (91%) |
300 (16%) |
300 (13%) |
285 (7%) |
300 (~10%) |
| Median age in years (IQR) | 35 (30–42) | 35 (30–42) | 38 (32–44) | 38 (33–45) | 37 (32–44) | 41 (35–49) | 38 (33–46) | 35 (30–43) | 35 (28–42) | 37 (31–42) |
| Female sex (%) | 198 (66.0) | 216 (72.0) | 196 (65.8) | 581 (64.6) | 190 (63.5) | 179 (60.3) | 193 (64.3) | 197 (65.7) | 191 67.0) | 162 (54.0) |
| Type of ART (%) | ||||||||||
| 2 NRTI +1 NNRTI | 298 (99.3) | 269 (89.7) | 298 (100) | 786 (87.3) | 291 (97.3) | 286 (96.3) | 298 (99.3) | 287 (95.7) | 253 (88.8) | 295 (98.3) |
| 3 NRTI | 0 (0.0) | 0 (0.0) | 0 (0.0) | 22 (2.5) | 0 (0.0) | 2 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 2 NRTI +1 PI | 2 (0.7) | 31 (10.3) | 0 (0.0) | 92 (10.2) | 8 (2.7) | 9 (3.0) | 2 (0.7) | 13 (4.3) | 32 (11.2) | 5 (1.7) |
| TDF (%) | 39 (13.0) | 87 (29.0) | 191 (64.1) | 303 (33.7) | 122 (40.8) | 122 (41.1) | 243 (81.0) | 44 (14.7) | 61 (21.4) | 265 (88.3) |
| HBsAg-positivity (%) | 5/35 (14.3) | 16/76 (21.1) | 2/12 (16.7) | 10/37 (27.0) | 0/2 (0.0) | 25/135 (18.5) | 13/279 (4.7) | 6/30 (20.0) | 4/94 (4.3) | 7/59 (11.9) |
IQR: interquartile range, ART: antiretroviral therapy, NRTI: nucleoside reverse-transcriptase inhibitors, NNRTI: non-nucleoside reverse-transcriptase
Inhibitors, PI: protease inhibitors, TDF: tenofovir; HBsAg: Hepatitis B surface antigen